Clinical study of Saccharomyces boulardii in prevention of secondary diarrhea caused by neonatal infectious pneumonia
Author(s): GAO Hai-liang, HU Xu-dong, Department of Pediatric, Maternal and Child Health Care Center of Yanan, People’s Hospital of Yanchuan County
Pages: 1040-1043
Year: 2014 Issue: 9
Journal: World Phytomedicines
Keyword: Saccharomyces boulardii; Montmorillonite Powder; infectious pneumonia; secondary diarrhea;
Abstract: objective To investigate the clinical efficacy of Saccharomyces boulardii in the prevention of secondary diarrhea caused by neonatal infectious pneumonia. Methods Patients with neonatal infectious pneumonia were randomly divided into control(54 cases)and treatment(54 cases) groups. All patients were given antibiotics and support treatment such as rehydration and vitamin. Patients in the treatment group were po administered with S. boulardii while taking antibiotics, 125 mg/time, twice daily. Patients with diarrhea in two groups were po administered with Montmorillonite Powder, 1.0 g/time, 3 times daily, and were given rehydration treatment until they were cured. Two groups were continuous treated for 14 d. After treatment, the treatment efficacy was evaluated, while the cellular immunological indexes were tested. Results The total effective rates of the treatment and control groups were 94.44% and 75.93%, respectively, with the significant difference between the two groups(P < 0.05). The incidence of diarrhea in treatment group was 38.89%, while that in the control group was 61.11%. In the treatment group, diarrhea occurred later than the control group, and the number of diarrhea per day in treatment group was less than that in the control group, while the duration of diarrhea in treatment group was also significantly shorter than that in the control group, and the difference was statistically significant between the two groups(P < 0.05). After treatment, CD4+ and CD4+/CD8+ of the treatment group increased, CD8+ decreased, with statistically significant difference before and after treatment(P < 0.05). Those detection indexes were compared with control group, and difference was statistically significant(P < 0.05). Conclusion S. boulardii has a good clinical efficacy in the prevention of secondary diarrhea caused by neonatal infectious pneumonia, and can improve immunity of patients, which is worthy of clinical application.
Pages: 1040-1043
Year: 2014 Issue: 9
Journal: World Phytomedicines
Keyword: Saccharomyces boulardii; Montmorillonite Powder; infectious pneumonia; secondary diarrhea;
Abstract: objective To investigate the clinical efficacy of Saccharomyces boulardii in the prevention of secondary diarrhea caused by neonatal infectious pneumonia. Methods Patients with neonatal infectious pneumonia were randomly divided into control(54 cases)and treatment(54 cases) groups. All patients were given antibiotics and support treatment such as rehydration and vitamin. Patients in the treatment group were po administered with S. boulardii while taking antibiotics, 125 mg/time, twice daily. Patients with diarrhea in two groups were po administered with Montmorillonite Powder, 1.0 g/time, 3 times daily, and were given rehydration treatment until they were cured. Two groups were continuous treated for 14 d. After treatment, the treatment efficacy was evaluated, while the cellular immunological indexes were tested. Results The total effective rates of the treatment and control groups were 94.44% and 75.93%, respectively, with the significant difference between the two groups(P < 0.05). The incidence of diarrhea in treatment group was 38.89%, while that in the control group was 61.11%. In the treatment group, diarrhea occurred later than the control group, and the number of diarrhea per day in treatment group was less than that in the control group, while the duration of diarrhea in treatment group was also significantly shorter than that in the control group, and the difference was statistically significant between the two groups(P < 0.05). After treatment, CD4+ and CD4+/CD8+ of the treatment group increased, CD8+ decreased, with statistically significant difference before and after treatment(P < 0.05). Those detection indexes were compared with control group, and difference was statistically significant(P < 0.05). Conclusion S. boulardii has a good clinical efficacy in the prevention of secondary diarrhea caused by neonatal infectious pneumonia, and can improve immunity of patients, which is worthy of clinical application.
Related Articles